Meeting
2013 Breast Cancer Symposium
The prospective estimation of blood serum free IGF-1, insulin concentration and body mass index as a prognostic factor for breast cancer patients.
Authors
Elzbieta Nowara
Center of Oncology and Institute of Oncolgy, Gliwice, Poland
Elzbieta Nowara , Joanna Huszno , Katarzyna Drosik-Rutowicz , Ewa Nowara , Barbara Maslyk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Local/Regional Therapy,Risk Assessment, Prevention, Detection, and Screening
Sub Track
High Risk
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 47)
DOI
10.1200/jco.2013.31.26_suppl.47
Abstract #
47
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.
First Author: Peter Cornelius
Poster
2018 ASCO Annual Meeting
Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): Results of CALGB (Alliance) 70806.
First Author: Marie Wood
Poster
2013 Genitourinary Cancers Symposium
Serum IGF-1 levels are decreased in men with advanced prostate cancer treated with the ERα agonist, gtx-758.
First Author: Evan Y. Yu
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah